RELESTAT

This brand name is authorized in Austria, Brazil, Hong Kong SAR China, Ireland, Israel, New Zealand, Poland, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug RELESTAT contains one active pharmaceutical ingredient (API):

1	Epinastine UNII GFM415S5XL - EPINASTINE HYDROCHLORIDE
	Epinastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H1-receptor and has affinity for the histamine H2receptor. Epinastine also possesses affinity for the α1, α2, and 5-HT2–receptors.
	Read more about Epinastine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RELESTAT Eye drops, solution	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01GX10	Epinastine	S Sensory organs → S01 Ophthalmologicals → S01G Decongestants and antiallergics → S01GX Other antiallergics
Discover more medicines within S01GX10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	501006101135311, 501006102131311
ES	Centro de información online de medicamentos de la AEMPS	65574
GB	Medicines & Healthcare Products Regulatory Agency	56514
HK	Department of Health Drug Office	53472
IE	Health Products Regulatory Authority	43652
IL	מִשְׂרַד הַבְּרִיאוּת	4942
NZ	Medicines and Medical Devices Safety Authority	11284
PL	Rejestru Produktów Leczniczych	100134915
SG	Health Sciences Authority	13817P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699490561232
ZA	Health Products Regulatory Authority	37/15.4/0691